Literature DB >> 21768925

Addiction issues in prescribing opioids for chronic nonmalignant pain.

Michael Weaver1, Sidney Schnoll.   

Abstract

This article provides an overview of central issues in chronic nonmalignant pain management with a focus on prescribing opioid analgesics. Definitions are provided for terminology regarding pain and addiction. Epidemiology of addiction among patients with chronic nonmalignant pain is reviewed. Benefits and complications of opioid therapy are discussed, along with recent regulatory issues for prescribers and use of medication agreements. Nonopioid treatments are reviewed. A standardized approach to chronic nonmalignant pain reduces stigma and improves patient care, therefore, an algorithm is presented for management of chronic nonmalignant pain.

Entities:  

Year:  2007        PMID: 21768925     DOI: 10.1097/ADM.0b013e3180473bec

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  5 in total

1.  Identifying prescription opioid use disorder in primary care: diagnostic characteristics of the Current Opioid Misuse Measure (COMM).

Authors:  Ellen C Meltzer; Denis Rybin; Richard Saitz; Jeffrey H Samet; Sonia L Schwartz; Stephen F Butler; Jane M Liebschutz
Journal:  Pain       Date:  2010-12-21       Impact factor: 6.961

2.  Opioid deaths in rural Virginia: a description of the high prevalence of accidental fatalities involving prescribed medications.

Authors:  Martha J Wunsch; Kent Nakamoto; George Behonick; William Massello
Journal:  Am J Addict       Date:  2009 Jan-Feb

Review 3.  Prescription Sedative Misuse and Abuse.

Authors:  Michael F Weaver
Journal:  Yale J Biol Med       Date:  2015-09-03

4.  Spanish Validation of the COMM Scale to Assess the Misuse of Prescription Opioids in Patients with Chronic Noncancer Pain.

Authors:  Ángela Reyes-Pérez; Alicia E López-Martínez; Rosa Esteve; Carmen Ramírez-Maestre
Journal:  Int J Ment Health Addict       Date:  2022-03-21       Impact factor: 11.555

5.  Eggshell membrane: a possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies.

Authors:  Kevin J Ruff; Dale P DeVore; Michael D Leu; Mark A Robinson
Journal:  Clin Interv Aging       Date:  2009-06-09       Impact factor: 4.458

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.